Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/471697
Genetic Engineering & Biotechnology News | GENengnews.com | MARCH 15, 2015 | 37 Reprints Karen Ballen 914-740-2194 reprints@GENengnews.com GEN offers reprints of individual articles — in printed or electronic form — to increase awareness of your product or company. Order today! Catalyst Pharmaceuticals named Richard J. Daly and Donald A. Denkhaus to its board of directors...3-V Biosciences welcomed Rekha Hemrajani as CFO, svp of business and fnancial operations...Steven J. Swanson, Ph.D., joined ImmunoCellular Therapeutics as svp of research...Pathway Genomics hired Anja Kammesheidt, Ph.D., as vp of research and development...CannaPhar- maRx added Christopher P. Schnittker as CFO...Regen BioPharma hired Todd Caven as CFO...Bob Baltera is now CEO of Laguna Pharmaceuticals...John F. Glenn is the new CFO of Armetheon. Vigilant Biosciences hired Greg Stan- ley as its vp of global sales and market- ing and elected Timothy C. Barabe to its board of directors...GTx appointed Robert J. Wills, Ph.D., to its board of di- rectors...Mitra Biotech named Eric Ro- winsky, M.D., to its scientifc advisory board...Cosmederm Bioscience added Steve Massah as COO...Perry Calias, Ph.D., joined Pharming as CSO...InVi- vo added Lorianne Masuoka, M.D., as CMO. Vaccinogen added Peter Morsing, Ph.D., as head of business develop- ment...VistaGen Therapeutics elected Gerard Sanacora Ph.D., M.D., to its clinical and scientifc advisory board... Dynavax appointed Laura Brege to its board of directors and chair of the audit committee...Dance Biopharm welcomed J. Tyler Martin, M.D., as president and member of its board of directors. DelMar Pharmaceuticals named Lyn- da Cranston to its board of directors... Aduro hired Sylvia R. Wheeler as svp, corporate affairs and investor relations... Tom Waddell, Ph.D., is the new vp of product development at Xagenic...Light- lake Therapeutics added Arvind Agraw- al as evp of medical affairs...Matthew Dallas joined CoLucid Pharmaceuticals as CFO and treasurer...Optivia Biotech- nology elected Jean-Michel Scherrmann, to its scientifc advisory board. Exact Sciences appointed Michael S. Wygza to its board of directors...Cancer Genetics hired Randy Goodman, Ph.D., as director of reimbursement and clini- cal revenue cycle management...Circas- sia named Lota S. Zoth as nonexecutive director, a member of its remuneration committee, and chair of its audit com- mittee...Peter Radovich is now vp of program leadership and business strat- egy at Global Blood Therapeutics. PerkinElmer elected Sylvie Grégoire to its board of directors... Cerenis Therapeutics welcomed Renee Beng- hozi, M.D., as CMO and Christian Chavy, M i c h a e l D a v i d s o n , M.D., and Marc Riv- iere, M.D., to its board of directors...Richard Van Bibbe, Ph.D., joined Aortica as vp of clinical affairs...Cidara Thera- peutics added Paul Daruwala as CCO and James Balkovec, Ph.D., as svp, research...Clin- ical Genomics hired Warren Bingham as vp, Asia Pacifc...Labcyte welcomed Chris Grimley as vp of marketing...Saad Usmani, M.D., is now acting CMO at SkylineDx. Sera Prognostics elected Arnold L. Oronsky, Ph.D., to its board of direc- tors...Biofortuna named Ian Johnson chairman to its board of directors... Glyconics Limited has appointed Jer- emy Williams to its board of directors... TapImmune hired Patrick D. Yeramian, M.D., as consulting medical director... Ronnie Meninger is now CEO, Hagai Stadler is director on the board of di- rectors, and Sammy Boussiba Ph.D., is chief scientist to the board of directors at Algatech...Symic Biomedical named Bar- bara Yanni and Bill Newell to its board of directors...Enumeral elected Paul J. Sekhri to its board of directors...Felix Karim, Ph.D., joined Compugen as vp of corporate and business development. Subscribe Clinical OMICs extends GEN's comprehensive coverage to the clinic by focusing on the application of revolutionary molecular technolo- gies in medical practice. To p i c s c ove re d i n c l u d e p e r s o n a l i z e d and precision medicine, next-gen sequencing, bioinformatics, reim- b u r s e m e n t , a n d b i o e t h i c s . To see past issues, recent news, and sub- scribe, go to: www.clinicalomics.com GEN'S NEW e-PUB Molecular Diagnostics in Personalized Medicine Send your People Announcements to people@GENengnews.com Kevin Hrusovsky is now CEO of Quanterix. Most recently, he was executive chairman of Quan- terix. Before that, Hrusovsky was presi- dent of PerkinElmer Life Sciences & Technology, CEO of Caliper Life Sci- ences, and CEO of Zymark. He is on the board of directors at Quan- terix, 908 Devices, SynapDx, and Solect Energy. P R O F I L E P R O F I L E P R O F I L E Vaccinogen appointed Hakan Edstrom and Ronald W. Kaiser to its board of directors. Edstrom is CEO of MannKind Corporation. Be- fore MannKind, he was president and senior corporate vp at Bausch & Lomb. Edstrom has more than 40 years of experience. Kaiser is a board member of the NACD. In the past, he was director at Tangoe. He has more than 35 years experience. P R O F I L E Robin L. Carmichael was promoted to president and COO at Helix BioMedix. Most recently, she was vp of of marketing and business development at the company, COO of DER- MAdoctor, and vp of marketing at ProCyte. Carmichael has over 20 years of industry experience. P R O F I L E PEOPLE Advanced Analytical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Afymetrix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40 Bachem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Bibby Scientifc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 BIOpHORETICS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Biosearch Technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Catalent Pharma Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Clinical OMICs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 Douglas Scientifc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 EMD Millipore . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 22,23 GEN/CDI webinar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 GEN/Clinical OMICs webinar. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 GEN/Waters webinar . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 Human Gene Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Illumina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Informa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 Lonza Rockland. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Merck Millipore . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 22, 23 Mirus Bio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 OriGene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cover Tip Pall Life Sciences. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Sartorius Stedim Biotech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Sony Biotechnology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Tosoh Bioscience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Wacker-Chemie. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Waters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 A D V E R T I S E R I N D E X Mike McMullen is the new CEO of Agilent. Most recent- ly, he was president and COO at the company. Before that, he was presi- dent of Agilent's chemical analysis group. McMullen has 30 years of industry and senior manage- ment experience at Agilent. Before joining Agilent's predecessor HP, he worked at DuPont.